| 1.25 Data as of May 23 |  0.00 / 0.00%Today’s Change | 0.23 Today|||52-Week Range 2.13 | +108.33% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $15.3M |
Company Description
Soligenix, Inc. is a development stage biopharmaceutical company, which develops products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics. It operates through two business segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec and other biotherapeutic products. The Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine, and VeloThrax, its anthrax vaccine, and OrbeShield, its gastrointestinal acute radiation syndrome therapeutic. The company was founded in 1987 and is headquartered Princeton, NJ.
Employees
Shareholders
| Individual stakeholders | 0.99% |
| Mutual fund holders | -- |
| Other institutional | -- |
Top Executives
| Christopher J. Schaber, PhD | Chairman, President & Chief Executive Officer |
| Joseph Michael Warusz, MBA, CPA | Chief Financial Officer, Secretary & VP |
| Robert N. Brey, PhD | Chief Scientific Officer & Senior Vice President |
| Kevin J. Horgan, MD | Chief Medical Officer & Senior Vice President |
.
